Skip to main content
PDSB
NASDAQ Life Sciences

PDS Biotech Closes $11.3M Initial Tranche of Nant-Led PIPE, Redeems Yorkville Note

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.379
Mkt Cap
$22.249M
52W Low
$0.195
52W High
$1.55
52W Position info
94% above low
Off High info
76% below high
Rel. Volume info
6.0× avg
Market data snapshot near publication time

PDSB sits 94% above its 52-week low of $0.195 on elevated volume (6.0× avg).

Summary

PDS Biotech closed the first $11.3 million tranche of its Nant Capital-led PIPE, redeemed its Yorkville note for $4.6 million, and seated two Nant-affiliated directors.


Key Events · Financing and Capital Events · PDSB

  • Initial PIPE Closing

    Completed initial closing of the Nant Capital-led PIPE with gross proceeds of approximately $11.3 million at $0.2825 per share unit.

  • Securities Issued

    Issued 16,502,870 common shares, 23,498,156 pre-funded warrants, and 20,000,514 common warrants, creating substantial potential dilution.

  • Yorkville Note Redeemed

    Redeemed the Yorkville promissory note in full for approximately $4.6 million, eliminating the 10% interest debt obligation.

  • Board Appointments

    Dr. Patrick Soon-Shiong and James Banaag joined the board effective at closing; board waived Nasdaq independence requirement for Nant designees.


Analysis · PDSB · Life Sciences

A critical capital infusion has been secured with the initial closing of the Nant Capital-led PIPE, raising $11.3 million in gross proceeds at $0.2825 per share unit — a lifeline for a company with only $5.6 million in cash and a going concern warning. The Yorkville promissory note was also redeemed in full for $4.6 million, eliminating a 10% interest debt obligation. The securities issued include 16.5 million common shares, 23.5 million pre-funded warrants, and 20 million common warrants, creating substantial potential dilution. Effective at closing, Dr. Patrick Soon-Shiong and James Banaag joined the board, with the board waiving Nasdaq independence requirements for the Nant designees. The milestone closing could add another $11 million if PDS0301 reaches a Phase 3 protocol submission.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PDSB was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.2M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PDSB - Latest Insights

PDSB
Nov 13, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9822
Real-time Price: $0.7949 info
Change: -$0.1873 (-19%) info
Market Cap: $83.584M info
PDSB
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.7949 info
Change: -$0.2851 (-26%) info
Market Cap: $83.584M info
PDSB
Oct 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9521
Real-time Price: $0.7949 info
Change: -$0.1572 (-17%) info
Market Cap: $83.584M info
PDSB
Oct 14, 2026, 4:17 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.7949 info
Change: -$0.6151 (-44%) info
Market Cap: $83.584M info
PDSB
Sep 22, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8334
Real-time Price: $0.7949 info
Change: -$0.0385 (-5%) info
Market Cap: $83.584M info